Viridian Therapeutics (0K1R.L) Stock Price
$12.91 0%
to add to portfolio
AI Score
-
Alternative
4 -
Fundamental
6 -
Technical
6
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Viridian Therapeutics, AI stock picks, stock alerts and much more.
0K1R.L AI Stock Analysis
AI stock analysis for 0K1R.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Viridian Therapeutics (0K1R.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Viridian Therapeutics (0K1R.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Viridian Therapeutics (0K1R.L), currently trading at $12.91, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About 0K1R.L
-
Viridian Therapeutics, Inc.
-
Symbol
0K1R.L
-
Market
LSE
-
Industry
Biotechnology
-
Market Cap
1.1B
Similar Stocks
 |
Codexis 0I0X.L |
$2.11 0.4% |
3 |
 |
Oxford Nanopore Technologies plc ONT.L |
£117.9 0.3% |
6 |
 |
Sareum Holdings SAR.L |
£17.5 5.4% |
2 |
 |
Avacta Group Plc AVCT.L |
£35 5.4% |
3 |
 |
ImmuPharma IMM.L |
£2.58 1% |
5 |
News
0K1R.L Alternative Data
Web Traffic
Viridian Therapeutics receives an estimated 3728 monthly visitors to viridiantherapeutics.com.
-
Web Traffic
3728
-
Change from Previous Month
21.4%
-
3 Month Change
60.3%
-
YoY Change
60.3%
News Mentions
Viridian Therapeutics was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Twitter Followers
Viridian Therapeutics has 822 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.2% over the last month.
-
Twitter Followers
822
-
Daily Change
0%
-
1 Month Change
0.2%
-
3 Month Change
0.4%
Instagram Followers
Viridian Therapeutics has 628 Instagram Followers on its main Instagram account, up by 0.6% over the last month.
-
Instagram Followers
628
-
Daily Change
0.2%
-
1 Month Change
0.6%
-
3 Month Change
1.9%
LinkedIn Followers
14,072 are following Viridian Therapeutics on LinkedIn, up by 4.5% over the last month.
-
LinkedIn Followers
14072
-
Daily Change
0%
-
1 Month Change
4.5%
-
3 Month Change
18.4%
Job Postings
Viridian Therapeutics currenly has an estimated 13 open job postings.
-
Job Postings
13
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
8.3%
Reddit Mentions
Viridian Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
LinkedIn Employees
According to LinkedIn, Viridian Therapeutics has 186 employees.
-
LinkedIn Employees
186
-
Daily Change
1.1%
-
1 Month Change
0%
-
3 Month Change
12.7%
Business Outlook
According to employee reviews, the business outlook among employees at Viridian Therapeutics is 39 out of 100 (bearish).
-
Business Outlook
39
-
Change from Previous Month
34.5%
-
3 Month Change
0%
-
YoY Change
0%
0K1R.L Financials
0K1R.L Key Metrics
-
Total Revenue
$72K
-
Net Income
-$79.7M
-
Earnings per Share
-$1.17
-
Free cash flow
-$73.4M
-
EBITDA
-$78.7M
-
EBITDA Ratio
-1093.67
-
Total Assets
$742.4M
0K1R.L 2-year Revenue & Income
0K1R.L 2-year Free Cash Flow
0K1R.L Technicals
0K1R.L SMA
0K1R.L RSI
FAQ
What's the current price of Viridian Therapeutics (0K1R.L) Stock?
The price of an Viridian Therapeutics (0K1R.L) share is $12.91.
What's the market cap of Viridian Therapeutics?
The current market cap of Viridian Therapeutics is 1.1B.
Should I buy or sell 0K1R.L?
Viridian Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Viridian Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.
Is Viridian Therapeutics a good investment?
The current analysis of Viridian Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Viridian Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Viridian Therapeutics (0K1R.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Viridian Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Viridian Therapeutics (0K1R.L) that investors often compare it to?
Viridian Therapeutics (0K1R.L) is often compared to similar stocks such as Codexis, Oxford Nanopore Technologies plc, Sareum Holdings, Avacta Group Plc and ImmuPharma.
What is the forecast for Viridian Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Viridian Therapeutics' stock price to be around $12.96 in 2026. Starting from the current price of $12.91, this represents a 0.4% change in price, indicating a neutral outlook for the stock.
How to buy Viridian Therapeutics (0K1R.L) Stock?
Viridian Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Viridian Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.